Project Grant R44AI184104
Award Date
7/10/24
Completion Date
6/30/25
Dollars Obligated
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Wisconsin, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $238,500 to the University of California, San Diego (UC San Diego) to develop a novel electrochemical lateral flow assay (ELFA) for diagnosing tuberculosis (TB) from a single drop of blood. The objective is to demonstrate the analytical and clinical performance of this ELFA test, which aims to accurately...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $1,350,312 to develop a rapid phenotypic drug susceptibility test (termed TRE-DST) for tuberculosis (TB). The TRE-DST system utilizes novel fluorescent trehalose probes to detect live Mycobacterium tuberculosis and determine drug resistance, addressing limitations of current diagnostic methods. Key...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $999,316 to Pearl Diagnostics, Inc. to develop a Point of Care urine test to aid in the diagnosis of invasive aspergillosis (IA). IA was recently named by the WHO as an infection causing "critical" threats to public health, with unmet needs in both diagnostics and therapeutics. The funding supports the...
This $1,413,007 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development and evaluation of the CRISPR-TB diagnostic tool for detecting tuberculosis (TB) in children under 5 years old. The University of Washington is the primary grantee and will lead a large prospective study of 400 children with suspected TB. The project aims to expand upon prior successful...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,170 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Latde Diagnostics Corp., a woman-owned small business, to develop a rapid, equitable, lateral flow-based antibiotic susceptibility test (AST) for urinary tract infections (UTIs). The goal of this Phase I project is to demonstrate the feasibility of the Metabolic Amino Acid Phenotyping (MAAP) test kit to provide rapid AST...
This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
This federal Project Grant award of $787,171 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel 1,2,4-triazole and pyrrolidine compounds as potential treatments for tuberculosis (TB). The primary objectives are to demonstrate preclinical proof-of-concept for these compound classes, optimize their pharmacological properties, and investigate their unique mechanism of action compared...
This Project Grant award of $774,881, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855), supports research to develop pro-apoptotic small molecule host-directed therapies (HDTs) for the treatment of pulmonary tuberculosis (TB). The research aims to utilize these novel HDTs to shorten TB treatment duration, enhance antibiotic penetration, and prevent post-TB lung disease. The project leverages...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $163,698 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Magic Lifescience, Inc. in Mountain View, CA to develop a novel point-of-care molecular diagnostic assay for syphilis as part of a multiplexed genital ulcer disease (GUD) test panel. The key objectives are to: 1) develop a PCR-based, multiplexed molecular assay for Treponema pallidum (syphilis) and other GUD pathogens using giant...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $415,978 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Central Florida. The grant aims to identify novel boron-based inhibitors of mycobacterial class II aminoacyl-tRNA synthetases, which are essential enzymes for protein synthesis in Mycobacterium tuberculosis (MTB). The research will use a high-throughput screening assay to test a library of boron-containing...